(2R,4R)-2-hydroxymethyl-4-trifluoromethyl-N-[(1,1-dimethyl)ethoxycarbonyl]pyrrolidine | 497103-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2R,4R)-2-hydroxymethyl-4-trifluoromethyl-N-[(1,1-dimethyl)ethoxycarbonyl]pyrrolidine
• 英文别名: (2R,4R)-tert-butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate；tert-Butyl (2R,4R)-2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate
• CAS: 497103-76-1
• 化学式: C₁₁H₁₈F₃NO₃
• 分子量: 269.264
• InChiKey: CRSWFECHMDRHHV-HTQZYQBOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2R,4R)-2-hydroxymethyl-4-trifluoromethyl-N-[(1,1-dimethyl)ethoxycarbonyl]pyrrolidine 在 盐酸 、 copper(l) iodide 、 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 三乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 二甲基亚砜 、 乙酸乙酯 、 正丁醇 为溶剂， 90.0 ℃ 、101.33 kPa 条件下， 反应 10.0h， 生成 methyl 2-((2R,4R)-1-(4-hydroxyphenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetate
  参考文献：
  名称：

  Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

  摘要：

  G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote,glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly I selectiveand potent GPR40 agonists with a dual mechanism of action, promoting both ghicose-clependent insulin and incretin secretion. Employing strategies to increase fiolarity and the ratio of sp(3)/sP(2) character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

  DOI：

  10.1021/acs.jmedchem.7b00982
• 作为产物：
  描述：

  顺式-4-羟基-D-脯氨酸盐酸盐 在 N-甲基吗啉 、 吡啶 、 chromium(VI) oxide 、 sodium tetrahydroborate 、 氯化亚砜 、 硫酸 、 palladium 10% on activated carbon 、 四丁基氟化铵 、 氢气 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 丙酮 为溶剂， -10.0~110.0 ℃ 、101.33 kPa 条件下， 反应 16.92h， 生成 (2R,4R)-2-hydroxymethyl-4-trifluoromethyl-N-[(1,1-dimethyl)ethoxycarbonyl]pyrrolidine
  参考文献：
  名称：

  Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

  摘要：

  G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote,glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly I selectiveand potent GPR40 agonists with a dual mechanism of action, promoting both ghicose-clependent insulin and incretin secretion. Employing strategies to increase fiolarity and the ratio of sp(3)/sP(2) character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

  DOI：

  10.1021/acs.jmedchem.7b00982

文献信息

• [EN] PYRROLIDINE GPR40 MODULATORS<br/>[FR] MODULATEURS PYRROLIDINES DE GPR40
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014078609A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物：或其立体异构体，或其药物可接受的盐，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。
• [EN] PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES À MÉDIATION PAR COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2022066774A1

  公开（公告）日：2022-03-31

  This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement C1-mediated disorders.

  这份披露提供了用于治疗医学障碍的药物化合物，例如补体介导的障碍，包括补体C1介导的障碍。
• Synthesis of Boc-protected cis- and trans-4-trifluoromethyl-d-prolines
  作者：Xiao-long Qiu、Feng-ling Qing

  DOI：10.1039/b206719f

  日期：2002.9.11

  Both Boc-protected trans- and cis-4-trifluoromethyl prolines were synthesized starting from L-serine simultaneously. In our synthetic route, the key intermediate 4 was obtained through the reaction of Garner's aldehyde 1 with ylide 2 followed by trifluoromethylation with FSO2CF2COOMe–CuI. After hydrogenation followed by reduction of 4, the alcohol 5 was obtained in low diastereoselectivity, however, the two diastereoisomers could be separated easily by flash chromatography in the following steps. The bromide 8b obtained from the alcohol 5 in a straightforward fashion could not afford the desired cyclization product because of the strong electron-withdrawing properties of the trifluoromethyl group and the low ability of bromide as a leaving group. Instead, mesylation of alcohols 12a and 12b followed by treatment with potassium bis(trimethylsilyl)amide (KHMDS) afforded the desired cyclization products 13a and 13b respectively, which were transformed into Boc-protected cis- and trans-4-trifluoromethyl-D-prolines in a straightforward fashion.

  同时从L-丝氨酸出发，合成了Boc保护的反式和顺式4-三氟甲基脯氨酸。在我们的合成路线中，关键中间体4是通过加纳醛1与亚胺2反应，然后用FSO2CF2COOMe-CuI进行三氟甲基化反应获得的。在4氢化和还原后，获得了低立体选择性醇5，然而，通过以下步骤的快速色谱法可以很容易地将两种非对映异构体分离。由于三氟甲基基团的强吸电子性和溴化物作为离开基团的低能力，从醇5中直接获得的溴化物8b不能提供所需的环化产物。相反，醇12a和12b的甲磺化，然后用双(三甲基硅基)氨基钾(KHMDS)处理，分别得到了所需的环化产物13a和13b，它们被直接转化为Boc保护的顺式和反式4-三氟甲基-D-脯氨酸。